CDK4/6 inhibitors are essential to the optimal adjuvant treatment of high-risk HR-positive/HER2-negative early breast cancer. However, challenges remain in identifying patients eligible for this treatment. In this interactive case challenge, you will walk through a patient case and make clinical decisions to optimize care for a patient with high-risk HR-positive/HER2-negative early breast cancer. Topics include understanding eligibility criteria for adjuvant CDK4/6 inhibitors, strategies for counseling patients about monitoring requirements and treatment goals, optimal dosing, and adverse event management to promote treatment persistence.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
CME included with membership
| Free CME Activity | Free |
| Paid Activity (e.g. Breast/Lung Cancer Congress recordings) | $50 |
| Paid Activity (e.g. Hematologic Malignancies Congress recording) | $90 |
Collected from the provider’s public pages · source
Specialties served/covered
- Addiction Medicine
- Adolescent Medicine
- Anatomic & Clinical Pathology
- Colon & Rectal Surgery
- Communication & Shared Decision-Making
- Dermatopathology
- Evidence-Based Medicine & Research
- Gastroenterology
- Gastrointestinal Surgery
- General Surgery
- Geriatric Medicine
- Gynecologic Oncology
- Head & Neck Surgery
- Health Equity & Inclusion
- Hematology
- Hospice & Palliative Medicine
- Medical Genetics & Genomics
- Medical Leadership & Administration
- Medical Oncology
- Nephrology
- Neurology
- Obstetrics & Gynecology
- Pain Medicine
- Pediatric Hematology-Oncology
- Practice Management & Ethics
- Pulmonary Disease
- Radiation Oncology
- Surgical Oncology
- Thoracic Surgery
- Transplant Hepatology
- Urological Oncology
- Urology
- Cardio-Vascular
- Cross-Specialty
- ENT & Head Neck
- GI & Liver
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pain & Palliative
- Pathology & Lab
- Primary care
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- On-demand / recorded video
- includes Case study / clinical scenario
- includes Virtual patient / simulation
- Credit · Up to 1 credit
- Commercial Support
-
ReleasedAug 31, 2026
-
Last day to claim creditMar 1, 2027 5 months left
-
Clinical Care Options, LLC (dba Decera Clinical Education) Next-Generation Oral SERDs in Adjuvant ER-Positive/HER2-Negative Early Breast Cancer: Interrogating the Evidence for Clinical Integration
-
Efficient CME, CME Outfitters, LLC Reshaping the Paradigm in Hormone Receptor Positive, HER2-negative Early Breast Cancer: How Next Generation SERDs May Challenge the Adjuvant Treatment Landscape
-
American Society of Clinical Oncology Breast Cancer Local/Regional/Adjuvant (Oral Abstract Session) – 2026 ASCO Annual Meeting
-
National Comprehensive Cancer Network Team Strategies for Overcoming Challenges to Guideline-Concordant Care of High-Risk HR-Positive/HER2-Negative Early Breast Cancer
-
National Comprehensive Cancer Network Recorded Presentation from the NCCN 2026 Annual Conference: Breast Cancer Case Review
-
National Comprehensive Cancer Network The Next Frontier for CDK4/6 Inhibitors in Breast Cancer: Expert Strategies for Applying the Latest Guidelines and Advances in Practice
